The Rising Cost of Cancer Drugs and Cancer Research: Legal, Bioethical and Medical Considerations
Thursday, March 6, 2014; 6:00 PM - 9:00 PM
There is no charge for this program.
This program is sponsored by the Bioethical Issues Committee and co-Sponsored by the Health Law and insurance Law Committees, and will focus on the legal, bioethical and medical issues triggered by the escalating costs of cancer drugs, as well as the rising cost of cancer research in general. Among the questions posed will be: Do hospital formularies have a legal right to refuse to purchase cancer drugs with prohibitively high prices? Do health insurance companies have a legal right to deny reimbursement of such drugs? Is it equitable that only patients who can afford to pay for the newest generations of cancer drugs will have access to them? What role do large pharmaceutical, biotechnology and generic drug companies play in guiding medical research?
Does excessive regulation protect patients or impede the progress of medical research? Does legislation such as the Orphan Drug Act create incentives for developing new drugs? Will personalized medicine and new information about the human genome spur drug development in coming decades?
These and related concerns will be explored through an interdisciplinary panel, including a prominent bioethicist, a medical oncologist, and several attorneys with expertise in the representation of pharmaceutical and biotechnology entities, scientific research consortia and foundations, and academic medical centers. Discussion will examine whether the various stakeholders affected- patients, physicians, hospitals, pharmaceutical and biotech companies, and insurance companies - can arrive at a strategy that enables patients to receive the highest levels of treatment while also promoting innovation and advancement in therapeutic cancer research.
Moderators: Wendy J. Luftig, Chair, Bioethical Issues Committee (Introduction); Arthur Caplan, PhD, Director of Medical Ethics, NYU Langone Medical Centerr
Speakers: Arthur Caplan, PhD, Director of Medical Ethics, NYU Langone Medical Center; Michael C. Caldwell, MD, MPH, Public Health Leadership Fellow, Harvard School of Public Health and former Commissioner of Health for Dutchess County, New York ; Stephen M. Goodman, Pryor Cashman. Co-head of Mergers and Acquisitions Practice; David G. Greene, Locke Lord. Managing Partner New York Office; Linda A. Malak, Moses & Singer. Chair of Healthcare and Privacy and Cybersecurity Departments
Sponsored by: Bioethical Issues Committee, Wendy J. Luftig, Chair; Health Law Committee, Ron Lebow, Chair; Insurance Law Committee, Daniel A. Rabinowitz, Chair